TY - JOUR
T1 - Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer.
AU - Ratto, Carlo
AU - Cassano, Alessandra
AU - Cassano, Alessandra
AU - Longo, R.
AU - Ippoliti, M.
AU - Palazzotti, B.
AU - Crucitti, F.
AU - Barone, C.
PY - 1998
Y1 - 1998
N2 - umour growth is angiogenesis dependent. Some authors suggest a prognostic role of microvessel count in colorectal cancer. We tested the role of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) in the switch to the angiogenic phenotype in 35 patients with colorectal cancer at different stages of disease. We evaluated the two angiogenic factors, by enzyme-linked immunosorbent assay (ELISA), in tumour, peritumoral mucosa, pathological mesenteric and peripheral blood. We used ten endoscopic intestinal biopsies and ten peripheral blood samples from healthy subjects as control. bFGF was significantly lower in tumour tissues and in peritumoral mucosas than in healthy mucosas, whereas VEGF was up-regulated in tumours but not in peritumoral mucosa. Both angiogenic factors were greatly increased in mesenteric blood. VEGF tumour and serum levels were significantly correlated with the stage of disease. bFGF tumour and serum concentration were not correlated with the stage of disease. The high levels of bFGF in mesenteric blood suggest that this growth factor might be abnormally released from tumour tissue and peritumoral mucosa and could function as an early effector in the switch to the angiogenic phenotype. In contrast, VEGF, whose levels show a significant correlation with the stage of disease, could act in a following step, supporting tumour progression.
AB - umour growth is angiogenesis dependent. Some authors suggest a prognostic role of microvessel count in colorectal cancer. We tested the role of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) in the switch to the angiogenic phenotype in 35 patients with colorectal cancer at different stages of disease. We evaluated the two angiogenic factors, by enzyme-linked immunosorbent assay (ELISA), in tumour, peritumoral mucosa, pathological mesenteric and peripheral blood. We used ten endoscopic intestinal biopsies and ten peripheral blood samples from healthy subjects as control. bFGF was significantly lower in tumour tissues and in peritumoral mucosas than in healthy mucosas, whereas VEGF was up-regulated in tumours but not in peritumoral mucosa. Both angiogenic factors were greatly increased in mesenteric blood. VEGF tumour and serum levels were significantly correlated with the stage of disease. bFGF tumour and serum concentration were not correlated with the stage of disease. The high levels of bFGF in mesenteric blood suggest that this growth factor might be abnormally released from tumour tissue and peritumoral mucosa and could function as an early effector in the switch to the angiogenic phenotype. In contrast, VEGF, whose levels show a significant correlation with the stage of disease, could act in a following step, supporting tumour progression.
KW - Angiogenic factor
KW - Basic fibroblast growth factor
KW - Colorectal cancer
KW - Enzyme-linked immunosorbent assay
KW - Vascular endothelial growth factor
KW - Angiogenic factor
KW - Basic fibroblast growth factor
KW - Colorectal cancer
KW - Enzyme-linked immunosorbent assay
KW - Vascular endothelial growth factor
UR - http://hdl.handle.net/10807/181230
U2 - 10.1038/bjc.1998.575
DO - 10.1038/bjc.1998.575
M3 - Article
SN - 0007-0920
VL - 78
SP - 765
EP - 770
JO - British Journal of Cancer
JF - British Journal of Cancer
ER -